RxDoctor Payments Data

Richard Lau, MD

Internal Medicine · Honolulu, HINPI 1609951797

Payments from drug & device makers

$2,488in general payments, 2019–2025

Across 123 payments — averaging $20.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$607
  • Novo Nordisk$479
  • Kowa Pharmaceuticals America, Inc.$442
  • Pfizer$216
  • AstraZeneca$211
  • Johnson & Johnson$148
  • plus $385 from 8 others

What the payments were for

  • Food & beverage$2,488100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,488 in reported general payments places this provider in the 80th percentile of 655 internal medicine providers in Hawaii.

See all internal medicine providers in Hawaii

Medicare billing

Part B allowed, 2024
$89,204
Medicare patients
214
Services billed
764

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin89$119,767
EliquisApixaban82$110,314
OzempicSemaglutide71$103,032
FarxigaDapagliflozin Propanediol48$61,617
MounjaroTirzepatide13$25,827
InvokanaCanagliflozin13$22,044
JanuviaSitagliptin Phosphate14$21,038
RybelsusSemaglutide13$19,262
XareltoRivaroxaban12$18,159
Atorvastatin Calcium507$13,995
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$13,110
Pravastatin Sodium341$8,596
Novolog FlexpenInsulin Aspart33$8,370
Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril203$7,670
LivaloPitavastatin Calcium14$7,638

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$479$122,29484 claims
Boehringer IngelheimJardiance$84$119,76789 claims
PfizerEliquis$216$110,31482 claims
AstraZenecaFarxiga$211$61,61748 claims
Johnson & JohnsonInvokana, Xarelto$148$40,20325 claims
Lilly USA, LLCMounjaro$607$25,82713 claims
Kowa Pharmaceuticals America, Inc.Livalo$442$7,63814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 655 internal medicine providers in Hawaii.

Other internal medicine in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →